Differential Effects of Oral and Intranasal Oxytocin on Attention Control

NCT ID: NCT04815395

Last Updated: 2021-03-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 151 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-19
• Study Completion Date: 2021-01-01

Brief Summary

The main aim of the present study is to investigate whether oxytocin (24IU) via different routes have divergent effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Detailed Description

Previous studies have demonstrated oral and intranasal oxytocin's divergent effects on arousal rating and neural responses to emotional faces, however, it remains unclear whether different routes of oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493515 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored oral and intranasal oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare oxytocin's effects on attention control to social emotional stimuli via different routes. To this end data from subjects who underwent intranasal oxytocin administration (n = 33, NCT03486925) will be compared with data from subjects who underwent oral oxytocin or placebo administration (n = 36, or 37 respectively; NCT04493515). To further control for non-treatment related factors the intranasal placebo and oral placebo groups from the previous studies (ClinicalTrials.gov ID: NCT03486925 and NCT04493515) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Oral Oxytocin

Oxytocin (24IU) orally

Group Type: EXPERIMENTAL

Oxytocin

Intervention Type: DRUG

Administration of oxytocin (24IU) orally

Intranasal Oxytocin

Oxytocin (24IU) intranasally

Group Type: EXPERIMENTAL

Oxytocin

Intervention Type: DRUG

Administration of oxytocin (24IU) intranasally

Oral Placebo

Placebo orally

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Administration of placebo orally

Interventions

Oxytocin

Administration of oxytocin (24IU) orally

Intervention Type: DRUG

Oxytocin

Administration of oxytocin (24IU) intranasally

Intervention Type: DRUG

Placebo

Administration of placebo orally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male, healthy participants
• Non smokers

Exclusion Criteria

• Previous or current medical, psychiatric, neurological disorder
• Regular medication
• Use of any psychoactive substances in the 24 hours before experiment
• Contra-indications for eye-tracking data acquisition

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Keith Kendrick

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Keith Kendrick, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Electronic Science and Technology of China (UESTC)

Locations

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, China

Countries

China

Other Identifiers

UESTC-neuSCAN-80

Identifier Type: -

Identifier Source: org_study_id